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Tumour angiogenesis is initiated by angiogenic factors that are produced in large amounts by hypoxic tumour cells. The inhibition of
this step may lead to tumour-specific antiangiogenesis because normal tissues are not usually hypoxic. On the other hand, blocking a
biological function of endothelial cells is known to result in angiogenic inhibition. To produce a tumour-specific and powerful
antiangiogenesis, we determined whether potent angiogenic inhibition could be achieved by inhibiting the production of angiogenic
factors by hypoxic tumour cells and simultaneously blocking certain angiogenic steps in endothelial cells under normoxia. We focused
on the 2-nitroimidazole moiety, which is easily incorporated into hypoxic cells and exhibits its cytotoxicity as hypoxic cytotoxin. We
designed and synthesised 2-nitroimidazole derivatives designated as KIN compounds, and investigated their antiangiogenic activities
under normoxia using a chick embryo chorioallantoic membrane. KIN-841 (2-nitroimidazole 1-acetylhydroxamate) showed a potent
angiogenic inhibition in a dose-dependent manner. This compound inhibited the proliferation of bovine pulmonary arterial endothelial
(BPAE) cells more strongly than that of tumour cells, such as Lewis lung carcinoma (3LL) cells, under normoxia. The inhibition of cell
proliferation by KIN-841 under hypoxia increased about five-fold compared to that under normoxia. Moreover, under hypoxia, KIN-
841 significantly decreased the excessive production of vascular endothelial cell growth factors induced by 3LL cells as determined by
tritium-labelled thymidine ([
3H]thymidine) incorporation into BPAE cells and by ELISA. Intraperitoneal administration of KIN-841
suppressed 3LL-cell-induced in vivo angiogenesis in the mouse dorsal air sac system. These results indicate that the regulation of the
production of angiogenic factors by hypoxic tumour cells is a useful target for tumour-specific angiogenesis inhibition, and that KIN-841,
which causes simultaneous direct inhibition of endothelial cell function and production of angiogenic factors by hypoxic tumour cells, is
a very potent inhibitor of tumour-specific angiogenesis. Thus, the potential for clinical use of KIN-841 as an antitumour drug is very high.
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Angiogenesis is the formation of new blood vessels, and is essential
for tissue development, regeneration and remodelling (Folkman
and Shing, 1992). Angiogenesis also plays an important role in
many pathological processes, such as growth and metastasis of
solid tumour, diabetic retinopathy, rheumatoid arthritis and
psoriasis. The inhibition of angiogenesis results in a suppression
of these diseases.
The initiation of angiogenesis is associated with some changes in
the environment affecting the equilibrium between angiogenic
factors and inhibitors. Hypoxia is considered as the leading cause
of angiogenesis. In solid tumours, hypoxia exists between the
aerobic region near the capillary blood vessels and the anaerobic
region where necrotic cells are present. Hypoxia is a common
feature of human and animal tumours (Moulder and Rockwell,
1984; Urtasun et al, 1986). Recently, the expression of vascular
endothelial growth factor (VEGF) was shown to increase
significantly in human gliomas under hypoxic conditions (Shweiki
et al, 1992). In human melanoma cells xenografted to nude mice,
the mRNAs coding for VEGFs were significantly elevated under
hypoxia, which resulted in tumour angiogenesis (Potgens et al,
1995). Hypoxia thus upregulates the expression of VEGF in
tumour cells, which subsequently leads to angiogenesis. Therefore,
the downregulation of the production of angiogenic factors by
hypoxic tumour cells is a potential therapeutic method of inhibiting
tumour-specific angiogenesis. On the other hand, inhibition of
certain steps in the angiogenic process in endothelial cells, such as
proliferation, migration and tube formation, undoubtedly results in
antiangiogenesis. Simultaneously reducing the levels of angiogenic
factors in hypoxic tumour cells and blocking the biological function
of endothelial cells under normoxia can induce much more potent
angiogenic inhibition in solid tumours.
Hypoxic tumour cells represent a significant problem in
radiation therapy and chemotherapy since they are resistant to
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sX-ray and antitumour drugs. The use of a radiosensitiser with an
affinity for hypoxic tumour cells and a probe for the detection and
quantitation of hypoxia regions in tumours is important for
developing appropriate therapeutic modalities against hypoxic
tumour cells. Nitroimidazole derivatives have been studied
extensively for use as radiosensitisers (Sheldon et al, 1974; Brown,
1975) and molecular markers of hypoxic regions in solid tumours
(Walton and Workman, 1987; Aboagye et al, 1995). 2-Nitroimi-
dazole derivatives, such as misonidazole and etanidazole, have
been reported to have potent radiosensitising ability (Sheldon et al,
1974; Brown et al, 1981), and have been clinically studied
regarding their application in the radiotherapy of patients with
malignant tumours (Chang et al, 1998; Grigsby et al, 1999). The
efficiencies of nitroimidazoles as hypoxic radiosensitisers depend
on the selective and irreversible binding to the reactive metabolite
of the nitro group having one-electron reduction potentials to
target molecules in hypoxic tumour cells (Adams et al, 1979).
Although nitroimidazole derivatives have been developed as
radiosensitisers, they also show preferential toxicity to hypoxic
cells as hypoxic cytotoxins (Stratford and Stephens, 1989;
Papadopoulou et al, 1996). The cytotoxicity of nitroheterocycles
such as misonidazole and etanidazole toward hypoxic cells is a
result of abstraction of hydrogen from target molecules by free
radicals formed in the reduction of the nitro group. The
efficiencies of both radiosensitising activity and cytotoxicity
toward hypoxic tumour cells depend on the nitro group of 2-
nitroimidazoles (Varghese and Whitmore, 1980; Bump et al, 1983).
We designed and synthesised 2-nitroimidazole derivatives termed
KIN compounds, and showed that KIN-802 and KIN-806 are
potent hypoxic cell radiosensitisers (Hori et al, 1989; Nagasawa
et al, 1992).
In this study, we achieved potent inhibition of tumour-specific
angiogenesis by inhibiting certain angiogenic steps under both
normoxia and hypoxia using the novel hypoxic-dependent 2-
nitroimidazole KIN-841.
MATERIALS AND METHODS
Compounds
All the KIN compounds tested (namely KIN-801, KIN-804, KIN-
806, KIN-808, KIN-811, KIN-831 and KIN-841), which were 2-
nitroimidazole derivatives with a moiety of –(CH2)nCONHR in the
side chain, were synthesised and their structures were identified
based on the physical and spectral data as described previously
(Hori et al, 1989; Nagasawa et al, 1992). Misonidazole, etanidazole
and 2-nitroimidazole were obtained from Nippon Roche (Tokyo,
Japan). The anti-mouse VEGF polyclonal antibody and ELISA kit
for the determination of mouse VEGFs were purchased from R&D
Systems Inc. (Minneapolis, MN, USA).
Cells
Bovine pulmonary arterial endothelial (BPAE) cells were obtained
from Dr T Takano (Jintan Terumo, Kanagawa, Japan). Lewis lung
carcinoma and cultured Lewis lung carcinoma (3LL) cells were
from Dr T Sakurai (Keio University, Tokyo, Japan). 3LL cells were
grown in Eagle’s medium supplemented with 10% fetal calf serum
(FCS) and BPAE cells were maintained in Dulbecco’s MEM
containing 10% FCS.
Chick embryo chorioallantoic membrane assay
Angiogenic activity was assayed using a chick embryo chorio-
allantoic membrane (CAM) as described previously (Shimamura
et al, 2001). Using a 4-day-old chick embryo (Ohmiya Kakin
Laboratories, Ohmiya, Japan) in a shell, 10ml of sample mixed in
1% methyl cellulose/0.9% NaCl was applied to the ring on the
surface of the CAM. After 48h of exposure at 371C, a fat emulsion
(Mitsubishi Pharma Corporation, Osaka, Japan) was injected into
the CAM to visualise clearly the blood vessels. Each experimental
group included six eggs, and experiments were repeated five times.
Angiogenic inhibition was indicated by the presence of a 3-mm-
diameter avascular zone around the ring (Oikawa and Shimamura,
1996; Yamaji et al, 1999). Inhibition of angiogenesis (%) means
(number of eggs showing at least 3mm zone of inhibition)/
(number of eggs used in each experimental group)100.
Cell proliferation under normoxic condition
Cultured BPAE cells and 3LL cells were seeded on 24-multiwell
plates at 510
4cells per well in a medium containing 10% FCS.
After 24h of incubation, the medium was discarded and various
concentrations of KIN-841 in fresh medium containing 3% FCS
were added. On day 3, the cells were trypsinised and counted using
a Coulter counter. Each experimental group included five wells,
and experiments were repeated three times.
Cell proliferation under hypoxic condition
3LL cells were seeded on Petri dishes at 510
4cellsml
1 in a
medium containing 10% FCS. After 24h of incubation, the
medium was discarded and the cells were washed with PBS. Fresh
medium containing 5% FCS and various concentrations of KIN-
841 were added into the Petri dishes, which were incubated for 48h
under hypoxic conditions. For incubation under hypoxia, the cells
in the Petri dishes were arranged in acrylic Lucite chambers to
which a gas mixture (95% N2–5%CO 2) was infused at a flow rate
of 1lmin
1 (Iizuka et al, 1994). Control endothelial cells were
maintained under normoxia. The cells in the Petri dishes were
trypsinised and counted using a Coulter counter. Each experi-
mental group included five wells, and experiments were repeated
three times.
Angiogenic factor production
3LL cells were cultured in the medium containing 10% FCS. At
confluence, the medium was changed to a serum-free one with
or without various concentrations of KIN-841. After incubation
for 24h under normoxia or hypoxia, the conditioned medium
(CM) was collected for the assay of [
3H]thymidine incorporation
in BPAE cells and for ELISA. For [
3H]thymidine incorpora-
tion, 310
4 BPAE cells were seeded on 96-well plates. After
24h the medium was discarded, and serum-free medium
and the five-fold diluted CM obtained from 3LL cells treated
with or without KIN-841 were added to the wells. On the other
hand, for the assay of the direct effect of KIN-841 on BPAE cells,
an appropriately diluted KIN-841-free CM from normoxic or
hypoxic 3LL cells was mixed with various concentrations of
KIN-841 and added to the BPAE cell-seeded wells. For the
assay with anti-mouse VEGF-neutralizing antibody, a diluted CM
from hypoxic or normoxic 3LL cells was mixed with anti-
mouse VEGF antibody (1:1000) for the 24-h incubation at
41C, and then added to the BPAE cell-seeded wells for
[
3H]thymidine incorporation assay. The treated BPAE cells were
incubated for 8h, and then 37kBq per well of thymidine-
[methyl-
3H] (NEN, Wilmington, DE, USA) was added. After 16h
of incubation, the medium was discarded and the cells were
washed with PBS and lysed in 4% Na2CO3/2N NaOH. The
radioactivity in 20ml of the cell lysate was determined using a
scintillation counter. The presence of VEGF in the CM from 3LL
cells was evaluated using ELISA. Each experimental group
included three wells, and experiments were repeated three times.
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Millipore chambers covered with filters (0.45-mm pore size) were
filled with either saline or 410
6 3LL cells, and were implanted s.c.
in dorsal air sacs created surgically by injection of an appropriate
volume of air to 7-week-old female ICR mice (Charles River Co.
Ltd, Yokohama, Japan). The mice were administered with KIN-841
(200mgkg
–1 day
1) or saline intraperitoneally for 4 days between
days 1 and 6. On day 7, mice were killed under diethyl ether and
the skin was carefully removed. Each experimental group included
six mice, and experiments were repeated twice. Angiogenesis was
graded using four angiogenesis indices of 1, 2, 3 and 4 according to
the modified method previously described (Lee et al, 1987). Grade
1 means no angiogenesis, while grade 4 indicates the most
pronounced angiogenesis.
All surgical procedures were performed under pentobarbital
anesthesia (Dainabot, Osaka, Japan). The animal ethics in all
animal experiments met the standards required by the UKCCR
Guidelines for the Welfare of Animals on Experimental Neoplasia
(second edition), as stated in the ‘Instructions to Authors’ forms.
Statistical analysis
Results are presented as mean7s.e.m. Statistical comparisons were
performed using the paired Student’s t-test. DAS analysis was
performed according to the Mann–Whitney U-test. A probability
value of Po0.05 was considered significant.
RESULTS
Effect of KIN-841 on angiogenesis in CAM
The antiangiogenic activities of ten 2-nitroimidazole derivatives
(including seven KIN compounds (KIN-801, KIN-804, KIN-806,
KIN-808, KIN-811, KIN-831 and KIN-841), two known 2-
nitroimidazole derivatives (misonidazole and etanidazole) and 2-
nitroimidazole) were determined in the presence of 200mg CAM
1
using CAM assay under normoxic condition. KIN-808 and KIN-
841 were found to inhibit angiogenesis (52.372.9 and 75.371.7%,
respectively). On the other hand, the inhibitory activities of
misonidazole and etanidazole were low (17.873.8 and 38.771.9%,
respectively). Among the compounds tested, the most potent
inhibitor was KIN-841 with a CH2(CH2)2CONHOH moiety at the 1-
position of 2-nitroimidazole in the molecule (Figures 1 and 2A,B).
KIN-841 suppressed the in vivo angiogenesis dose-dependently
with an ED50 of 50mg CAM
1 (Figure 2C).
Effect of KIN-841 on proliferation of endothelial cells
and tumour cells under normoxia
BPAE cells and 3LL cells were incubated with various concentra-
tions of KIN-841 in the proliferation assay (Figure 3). KIN-841
showed a direct inhibitory effect on the proliferation of BPAE cells
at 10
4 M (Po0.05). On the other hand, the proliferation of 3LL
cells was not inhibited by 10
4 M KIN-841. KIN-841 showed a more
potent inhibition of the proliferation against the endothelial cells
than of tumour cells (Po0.05).
Effect of KIN-841 on proliferation of tumour cells under
hypoxia
Previously, all the compounds tested other than 2-nitroimidazole
in CAM assay under normoxia were reported to exhibit similar
high levels of radiosensitising activity against hypoxic tumour cells
(Nagasawa et al, 1992). The radiosensitising activity was shown to
correlate with specific cytotoxicity in hypoxic tumour cells.
Therefore, subsequent experiments under hypoxic condition were
carried out with the most potent angiogenic inhibitor under
normoxia, KIN-841. 3LL cells were cultured with or without KIN-
N
N
NO2
(CH2)3CONHOH
Figure 1 Structure of KIN-841.
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Figure 2 Inhibitory effect of KIN-841 on in vivo angiogenesis in CAM. No
(A) or 100mgml
1 (B) KIN-841 was added to the CAM surfaces of 4-day-
old fertilized eggs, and then the eggs were incubated for 48h as described
in Materials and Methods. KIN-841 produced an avascular zone
(surrounded by arrows), indicating angiogenic inhibition. (C) Dose-
dependent inhibition of in vivo angiogenesis in CAM by KIN-841.
aPo0.01 vs controls.
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(Figure 4). Under the hypoxic conditions, the cell growth was
slow and KIN-841 inhibited the proliferation of 3LL cells at
10
4–10
3 M (Po0.01). On the other hand, this inhibitory activity
was weak when the cells were cultured under normoxic conditions
(Po0.05 vs hypoxia). The inhibition of KIN-841 on 3LL cell
proliferation was about five times more potent under hypoxia than
under normoxia.
Effect of KIN-841 on production of angiogenic factor by
hypoxic tumour cells
It is well known that hypoxic tumour cells produce significant
amounts of many kinds of factors that initiate angiogenesis. To
determine whether KIN-841 suppresses the production of angio-
genic factors by 3LL cells under hypoxia, the serum-free CM was
obtained from 3LL cells that were treated with various concentra-
tions of KIN-841 under normoxia or hypoxia. The levels of the
angiogenic factors in the CM were measured by [
3H]thymidine
incorporation into BPAE cells (Figures 5A and B) and by ELISA
(Figure 5C). The CM from 3LL cells cultured under hypoxia
significantly stimulated thymidine uptake into BPAE cells com-
pared with that obtained from the cells cultured under normoxia
(P40.05, Figure 5A). This activity in CM of hypoxic tumour cells
was 1.8 times higher than that in normoxic cells. The stimulating
activity was decreased when the tumour cells were incubated with
KIN-841 under hypoxia (P40.01, Figure 5A). In contrast, the
direct addition of KIN-841 did not block the thymidine uptake
induced by the CM from 3LL cells (Figure 5B). However, the anti-
mouse VEGF antibody potently blocked the stimulating activity of
the CM from hypoxic tumour cells, suggesting that the angiogenic
factors in the CM are VEGFs (Figure 5B). Figure 5C shows the
levels of VEGF in the CM of 3LL cells treated with various
concentrations of KIN-841 under the same conditions as in
Figure 5A. In 3LL cells, VEGF production was significantly induced
by hypoxia (Po0.01), and KIN-841 at 10
5–10
4 M substantially
inhibited VEGF production (Po0.05).
Effect of KIN-841 on tumour-induced angiogenesis
To determine whether KIN-841 might have therapeutic value in
vivo in the treatment of tumour-induced angiogenesis, the effect of
KIN-841 on 3LL-cell-induced angiogenesis was investigated using
the mouse dorsal air sac method (Figure 6). In mice implanted
with a Millipore chamber containing saline, angiogenesis hardly
occurred (group A, Figure 6A). On the other hand, in the mice of
group B, implanted with a chamber containing 3LL cells and then
treated with saline, potent angiogenesis was induced (Figure 6B).
When the mice were intraperitoneally administered with
200mgkg
1day
1 of KIN-841 (group C, Figure 6C), the angio-
genesis was significantly suppressed. The angiogenesis indexes of
group B (3LL cells alone) and group C (3LL cells and KIN-841)
were 3.270.44 and 1.7570.20, respectively (Figure 6D). KIN-841
significantly inhibited in vivo angiogenesis induced by 3LL cells in
the dorsal air sac assay (Po0.05).
DISCUSSION
Tumour angiogenesis is a complex multistep process involving the
following: (1) production of angiogenic factors by tumour cells,
especially hypoxic tumour cells; (2) upregulation of the biological
functions of vascular endothelial cells by angiogenic factors; (3)
degradation of the basement membrane of endothelial cells by
enzymes; (4) migration of endothelial cells; (5) proliferation of
endothelial cells; and (6) tube formation of endothelial cells.
Interruptions in certain steps of this series of biochemical events
may prevent angiogenesis. In particular, the inhibition of the early
steps of the process may promote antiangiogenesis. The preven-
tion of the first step of angiogenesis that involves the production of
angiogenic factors by hypoxic tumour cells is potently effective in
promoting tumour-specific antiangiogenesis.
There are many factors implicated in angiogenesis. The
production of several angiogenic factors, including VEGF, bFGF
and PDGF (Minchenko et al, 1994; Gleadle et al, 1995; Kuwabara
et al, 1995), is upregulated by hypoxia. In solid tumours, a more
rapid increase in the number of oxygen-consuming tumour cells
than can be sustained by the oxygen supply to the cells from the
microvasculature occurs, resulting in tissue hypoxia. Continuous
hypoxia results in the expression of the genes coding for
angiogenic factors, which are produced in secretory forms.
Angiogenic factors act on their receptors on endothelial cells in
an autocrine and paracrine manner, thereby causing the activation
of endothelial cells, which leads to angiogenesis and subsequent
progressive tumour growth and metastasis. Therefore, the preven-
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Figure 3 Inhibitory effect of KIN-841 on proliferation of BPAE cells
and 3LL cells under normoxia. Cells were treated for 48h with KIN-841 at
the various concentrations indicated.
aPo0.05 vs controls;
bPo0.05 vs
normoxia.
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Figure 4 Inhibitory effect of KIN-841 on proliferation of 3LL cells under
hypoxia. Cells were treated for 48h with KIN-841 at the various
concentrations indicated under normoxia or hypoxia.
aPo0.05 vs controls;
bPo0.01 vs controls;
cPo0.05 vs normoxia.
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stion of the production of angiogenic factors in hypoxic tumour
cells may result in the potent inhibition of angiogenesis, tumour
growth and metastasis.
In this study, we attempted to (1) inhibit the production of
angiogenic factors in hypoxic tumour cells using 2-nitroimidazole
derivatives, which covalently bind to hypoxic tumour cells and are
cytotoxic against hypoxic tumour cells, and (2) simultaneously
disrupt the endothelial cell function using the same agent, to
achieve potent inhibition of tumour-specific angiogenesis. We
found the hypoxia-dependent 2-nitroimidazole KIN-841, with a
hydroxamate moiety in the side chain, to be the most potent
angiogenic inhibitor by an in vivo assay using the CAM under
normoxia (Figures 1 and 2).
In order to determine the antiangiogenic mechanism of KIN-
841, its effect on the proliferation of endothelial cells was
examined. KIN-841 inhibited the proliferation of vascular en-
dothelial cells under normoxia (Figure 3). Its inhibitory effect on
endothelial cells was more potent than that on tumour cells. These
results suggest that KIN-841 inhibits angiogenesis by disrupting
vascular endothelial cell growth. Under hypoxic conditions, KIN-
841 inhibited the proliferation of tumour cells more potently than
under normoxia (Figure 4). The CM from 3LL cells under
hypoxia could stimulate [
3H]thymidine incorporation into vascular
endothelial cells. This stimulating activity in CM was estimated to
be because of the presence of VEGFs (Figure 5B, C). In contrast,
the CM of KIN-841-treated hypoxic tumour cells decreased the
stimulating activity and VEGF level (Figure 5A, C). KIN-841 did
not directly inhibit the stimulating activity (Figure 5B). These
results indicated that KIN-841 can suppress the production of
angiogenic factors, VEGFs, derived from hypoxic tumour cells and
may inhibit tumour-specific angiogenesis.
There is no question regarding the importance of VEGFs in
angiogenesis and expansion of solid tumours, because VEGF
particularly affects vascular endothelial cells and, consequently,
stimulates all steps of angiogenesis. However, several reports
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Figure 5 Inhibitory effect of KIN-841 on the production of angiogenic
factor in 3LL cells under hypoxia. (A) Effect of 3LL cell-CM treated with
KIN-841 at the various concentrations indicated under normoxia or
hypoxia on [
3H]thymidine incorporation in BPAE cells.
aPo0.01 vs
normoxia controls;
bPo0.01 vs hypoxia controls. (B) Effects of KIN-841
and anti-VEGF antibody on stimulation of [
3H]thymidine incorporation in
BPAE cells by 3LL cell-CM incubated under normoxia or hypoxia.
aPo0.05
vs normoxia controls;
bPo0.05 vs normoxia controls;
cPo0.01 vs hypoxia
controls. (C) VEGF concentration in 3LL cell-CM treated with KIN-841 at
the various concentrations indicated under normoxia or hypoxia.
aPo0.05
vs normoxia controls;
bPo0.05 vs hypoxia controls;
cPo0.01 vs hypoxia
controls.
Figure 6 Inhibition of 3LL-cell-induced angiogenesis by KIN-841 as
determined using the mouse dorsal air sac method. Dorsal skin of the mice
7 days after implantation of a chamber filled with PBS alone (A) or 3LL cells
(B and C). The implanted mice were treated with 200mgkg
1day
1 of
KIN-841 for 4 days between days 1 and 6, intraperitoneally (C). In (D), the
grade of angiogenesis induced by 3LL cells is shown using the indexes
described in Materials and Methods.
aPo0.01 tumour-free controls;
bPo0.05 vs tumour controls.
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roles in angiogenesis (Hartmann et al, 1999; Koga et al, 2001;
Shimo et al, 2001). In melanoma cell lines, a strong correlation
between VEGF expression and tumorigenesis was not observed,
although VEGF production was induced under the hypoxic
condition (Hartmann et al, 1999). Angiogenin production was
reported to be upregulated in melanoma cell lines but not in
normal melanocytes under hypoxic condition. The level of
induction of angiogenin correlated with the metastatic potential
of the cell lines. Furthermore, a strong expression of angiogenin
was observed in melanomas and metastases from patients, but was
not observed in benign nevi. These indicated that angiogenin is the
most potent angiogenic factor in melanomas. Various approaches
to inhibiting angiogenic factor signalling pathways have been
adopted using specific antibodies against various angiogenic
factors. A monoclonal antibody against VEGF inhibited angio-
genesis and prevented tumour growth in solid tumours (Borg-
strom et al, 1996; Brekken and Thorpe, 2001). However, a specific
antibody against one angiogenic factor cannot completely inhibit
angiogenesis, which depends on two or more factors or a
different type of angiogenic factor. This problem may be overcome
if hypoxia-induced angiogenic factor-producing cells can be
attacked and the production of angiogenic factors by hypoxic
cells can be inhibited. KIN-841 may be able to inhibit the
production of all types of hypoxia-induced angiogenic factors in
tumour cells.
We further determined the effect of KIN-841 on tumour-induced
angiogenesis using the mouse dorsal air sac method. KIN-841
exhibited inhibitory activity on the angiogenic response triggered
by mouse malignant 3LL cells (Figure 6). This result suggested that
KIN-841 inhibits tumour growth and metastasis in vivo by
disrupting angiogenesis. Recently, the oxygen tensions in a neck
node of a squamous cell carcinoma and adjacent normal tissue
were measured (Adam et al, 1999). Normal tissue showed a typical
Gaussian distribution of oxygen tensions with a median value
between 40 and 60mmHg. On the other hand, tumours showed a
distribution of much lower oxygen tension with a median value of
less than 10mmHg. Since the oxygen tension in normal tissue is
slightly low, KIN-841 may express more potent in vivo anti-
angiogenesis because of its high affinity to hypoxic tumour cells
and slightly hypoxic endothelial cells.
In conclusion, potent inhibition of tumour-specific angiogenesis
can be induced by simultaneously preventing the production of
angiogenic factors by hypoxic tumour cells and vascular endothe-
lial cell function involved in cell proliferation under normoxia in
the presence of a novel hypoxia-dependent 2-nitroimidazole
derivative, KIN-841. Furthermore, the hypoxia-dependent KIN-
841 may be able to target effectively tumour-associated vascula-
tures and exhibit potent antiangiogenic activity in solid tumours
and prevent tumour metastasis.
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